8-K: Candel Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Program Update

Candel Therapeutics announced its full year 2023 financial results and provided updates on its clinical programs, including upcoming data readouts and FDA Fast Track Designations.

Summary

• Candel Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2023.
• The company highlighted progress in its clinical programs, including the publication of CAN-3110 trial results in Nature and multiple FDA Fast Track Designations.
• Candel anticipates six data readouts in 2024 across its platforms, including a potentially registrational phase 3 trial in prostate cancer.
• Research and development expenses increased to $24.5 million for the full year 2023, compared to $20.8 million in 2022.
• The net loss for the full year 2023 was $37.9 million, compared to a net loss of $18.8 million in 2022.
• Cash and cash equivalents were $35.4 million as of December 31, 2023, down from $70.1 million the previous year.
• The company expects its current cash to fund operations into the fourth quarter of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive clinical developments and FDA designations, the significant increase in net loss and decrease in cash reserves raise concerns about the company's financial stability. The need for a potential capital raise is a negative signal.

Positives

• Candel secured multiple FDA Fast Track Designations for its key drug candidates.
• The publication of CAN-3110 trial results in Nature highlights the scientific validity of their approach.
• Initial data from CAN-2409 trials show promising survival benefits and immune responses.
• The company has multiple data readouts expected in 2024, indicating a busy year of clinical progress.

Negatives

• The company's net loss increased significantly to $37.9 million for the full year 2023.
• Cash reserves decreased substantially from $70.1 million to $35.4 million year-over-year.
• Research and development expenses increased to $24.5 million for the full year 2023.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• Clinical trial results may differ from interim data, impacting the perceived efficacy of their treatments.
• The company faces risks related to the timing and advancement of development programs.
• There are risks associated with obtaining and maintaining regulatory approval for their product candidates.

Future Outlook

Candel expects six data readouts across its three platforms in 2024, including a potentially registrational phase 3 clinical trial in prostate cancer, and anticipates its current cash will fund operations into the fourth quarter of 2024.

Management Comments

• 2023 was a significant year for Candel with two additional FDA Fast Track Designations for CAN-2409 and most recently Candel received FDA Fast Track Designation for CAN-3110 in February of 2024.
• We are also excited that initial results in CAN-3110s ongoing phase 1b clinical trial were published in the high-impact scientific journal, Nature.
• Initial patient data showed improved survival after experimental treatment with Candels investigational viral multimodal immunotherapies, as compared to standard of care, in non-small cell lung cancer (CAN-2409), pancreatic cancer (CAN-2409), and high-grade glioma (CAN-3110).
• In 2024, we are expecting six data readouts across our three platforms, which include novel clinical and biomarker data in lung cancer, pancreatic cancer, and brain cancer, and a potentially registrational phase 3 clinical trial in prostate cancer.

Industry Context

Candel's focus on multimodal biological immunotherapies aligns with the broader industry trend towards personalized cancer treatments. The company's progress in securing FDA Fast Track Designations and publishing clinical trial results in high-impact journals positions them as a notable player in the competitive oncology space.

Comparison to Industry Standards

• Candel's approach of using genetically modified adenovirus and herpes simplex virus (HSV) gene constructs is similar to other companies in the oncolytic virus space, such as Replimune and BioVex (now part of Amgen).
• The publication of CAN-3110 results in Nature is a significant achievement, comparable to other companies that have published in high-impact journals, such as Kite Pharma (now part of Gilead) with their CAR-T cell therapy.
• The FDA Fast Track Designations for multiple programs are a positive sign, similar to other companies that have received such designations for their oncology programs, such as Adaptimmune and bluebird bio.
• The increase in R&D expenses is typical for a clinical-stage biotech company, but the increase in net loss and decrease in cash position is a concern, and will need to be monitored against peers such as Iovance Biotherapeutics and Gritstone bio.

Related Party Transactions

• Research and development service revenue, related party, for each of the quarter and full year ended December 31, 2023 was $0, as compared to $31,000 and $125,000 for the quarter and full year ended December 31, 2022.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased cash position.
• Employees may be impacted by the company's financial situation and potential need for cost-cutting measures.
• Patients may benefit from the company's clinical advancements and potential new treatment options.
• Creditors may be concerned about the company's ability to repay debts given the current financial situation.

Next Steps

• The company will present new preclinical data at the 2024 AACR Annual Meeting in April.
• Phase 2 topline OS data for CAN-2409 in NSCLC is expected in Q2 2024.
• Phase 2 updated OS data for CAN-2409 in borderline resectable pancreatic cancer is expected in Q2 2024.
• Phase 2 topline data for CAN-2409 in low-to-intermediate-risk prostate cancer is expected in Q4 2024.
• Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer is expected in Q4 2024.

Key Dates

Keywords

Candel Therapeutics, Immunotherapy, Oncology, Clinical Trials, FDA Fast Track, CAN-2409, CAN-3110, Prostate Cancer, Pancreatic Cancer, Lung Cancer, Glioma, Financial Results